Patrick Hyland, MD
Advanced Heart Failure and Transplant Cardiology · Boston, MANPI 1528595402
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 29.1% of the total. Reporting peaked in 2023 at $451 and has fallen 72.6% since, to $124 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in MA, where the typical reported total is $6,286.
Across 30 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$296
- Daiichi Sankyo Inc.$127
- Abbott$124
- Amgen$124
- Pfizer$107
- Heartflow, Inc.$52
- plus $188 from 6 others
What the payments were for
- Food & beverage$1,018100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $296 |
| Daiichi Sankyo Inc. | 5 | $127 |
| Abbott | 1 | $124 |
| Amgen | 5 | $124 |
| Pfizer | 4 | $107 |
| Heartflow, Inc. | 2 | $52 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $41 |
| Boehringer Ingelheim | 1 | $31 |
| Abiomed | 1 | $31 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Merck | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- WAINUA$124
- CARDIOMEMS$124
How this compares
$1,018 in reported general payments places this provider in the 35th percentile of 35 advanced heart failure and transplant cardiology providers in Massachusetts.
See all advanced heart failure and transplant cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 12 | $19,148 |
| Metoprolol Succinate | 27 | $600 |
| Spironolactone | 20 | $171 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Boston
- Pablo Quintero PinzonBoston$137K
- Daniel ZlotoffBoston$96K
- Christina Vander PluymBoston$55K
- Monica AhluwaliaBoston$39K
- Stephanie MooreBoston$30K
- David DenofrioBoston$18K
- Robb KociolBoston$12K
- Marwa SabeBoston$12K
- Edward GrandinBoston$8K
- Kemar BrownBoston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.